Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;42(26):126464.
doi: 10.1016/j.vaccine.2024.126464. Epub 2024 Oct 20.

Anti-RBD IgG dynamics following infection or vaccination

Amira Harrache  1 , Kahina Saker  2 , Bouchra Mokdad  2 , Laurence Generenaz  2 , Carla Saade  2 , Sylvie Pons  2 , Jean-Baptiste Fassier  3 ; COVID-SER Study group; Antonin Bal  4 , Mary-Anne Trabaud  4 , Muriel Rabilloud  1 , Amna Abichou-Klich  1 , Sophie Trouillet-Assant  5
Affiliations
Free article

Anti-RBD IgG dynamics following infection or vaccination

Amira Harrache et al. Vaccine. .
Free article

Abstract

Identifying parameters influencing SARS-CoV-2 antibody dynamics post infection or vaccination is crucial for refining vaccination strategies. In a longitudinal analysis of 1340 samples from 375 healthcare workers, we characterized peak serological response and IgG half-life. Peak antibody titers post 2 vaccine doses were ∼ 20 times higher than natural infection; conversely, infected individuals had extended antibody half-life. Clinical and demographical factors such as BMI, age and smoking shaped peak response without affecting anti-RBD IgG half-life. A third mRNA vaccine dose increased peak antibody titers and prolonged half-life compared to the second dose. These findings underscore the diverse kinetics of SARS-CoV-2 antibody responses, which is influenced by immunization type/number and clinical factors.

Keywords: SARS-CoV-2 vaccine; antibody peak; clinical factors; half-life.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sophie Trouillet-Assant reports financial support was provided by Agence Nationale de Recherches sur le Sida et les Hépatites Virales. Sophie Trouillet-Assant reports a relationship with National Agency for Research on AIDS and Viral Hepatitis that includes: funding grants. Laurence Generenaz and Sylvie Pons are employees of bioMérieux SA, an in vitro diagnostic company. bioMérieux kindly provided all the serological kits. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Publication types

LinkOut - more resources